Endocrine Abstracts

Contents

• 15th Annual Multidisciplinary NET Medical Symposium NANETS 2022
• • Basic Science
  • • Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors

      ea0089b1
    • Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors

      ea0089b2
    • Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors

      ea0089b3
    • Simultaneous Inhibition of DNA Methylation and Histone De-acetylation for Enhanced SSTR2 Expression In Vitro

      ea0089b4
    • Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model

      ea0089b5
    • Detecting Cell Surface Expression of Calreticulin in Pancreatic Neuroendocrine Tumors Using a Novel [68Ga]-Radiolabeled Peptide

      ea0089b6
    • All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-Prolyl Cis-Trans Isomerase 1 Inhibition

      ea0089b7
    • CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors

      ea0089b8
    • Deletion of Notch1 Signaling in Pancreatic Neuroendocrine Tumors Reduces Metastatic Properties

      ea0089b9
    • Inhibition of Estrogen Receptor Alpha Radiosensitizes Neuroendocrine Tumors

      ea0089b10
    • Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors

      ea0089b11
    • Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors

      ea0089b12
    • Optical Genome Mapping: a Novel Approach to Identifying Structural Variants in Metastatic Neuroendocrine Tumors

      ea0089b13
    • Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: a Single Institutional Genomic Characterization Report

      ea0089b14
    • Targeting the TCA Cycle with Histone Deacetylase and Nicotinamide Phosphoribosyltransferase Inhibitors Uncovers a Critical Role for YAP1 in Neuroendocrine Cells

      ea0089b15
    • [212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

      ea0089b16
  • Clinical – Chemo/SSA/Biologics
  • • Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

      ea0089c1
    • Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

      ea0089c2
    • Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)

      ea0089c3
    • Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)

      ea0089c4
    • c-MET Expression in MEN1-associated Neuroendocrine Tumors

      ea0089c5
    • An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

      ea0089c6
    • Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

      ea0089c7
    • Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors

      ea0089c8
    • Correlation of MEN1 and DAXX Mutational Status with Response to Capecitabine and Temozolomide (CAPTEM) in Pancreatic Neuroendocrine Tumors

      ea0089c9
    • ACTH-secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series

      ea0089c10
    • Results from the Phase 1, Randomized, Open-Label, Cross-Over Study to Evaluate Pharmacokinetics of Three Escalating Doses of Oral Octreotide Capsules

      ea0089c11
    • Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study

      ea0089c12
    • Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization

      ea0089c13
  • Clinical – Nuclear Medicine/Interventional Radiology/Imaging
  • • Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT

      ea0089c14
    • Effectiveness and Safety of Re-Treatment With 177Lu-DOTATATE in Patients With Progressive NETs in the US: a Retrospective Real-World Study

      ea0089c15
    • Clinical Utility of Somatostatin Receptor Positron Emission Tomography Imaging Biomarkers for Characterization of Meningioma Among Incidental Central Nervous System Lesions

      ea0089c16
    • Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes

      ea0089c17
    • Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?List of participants and their roles in the submission

      ea0089c18
    • Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series

      ea0089c19
    • Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial

      ea0089c20
    • Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

      ea0089c21
    • The Role of 68Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors

      ea0089c22
    • Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of Dotatate PET scans

      ea0089c23
    • MIBG and DOTATATE Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

      ea0089c24
    • Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

      ea0089c25
    • Pre-therapy Functional Imaging with MIBG and DOTATATE to Guide Radiopharmaceutical Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

      ea0089c26
    • Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma

      ea0089c27
    • Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-related-pheochromocytoma

      ea0089c28
    • Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma

      ea0089c29
  • Clinical – Surgery/Applied Pathology
  • • Liver-Directed Therapy of Neuroendocrine Liver Metastases

      ea0089c30
    • Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets

      ea0089c31
    • Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

      ea0089c32
    • High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics

      ea0089c33
    • Grade Creep and the Importance of Tissue Sampling: Changes in Ki-67 and Grade in Serial Neuroendocrine Tumor Samples

      ea0089c34
    • Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis

      ea0089c35
    • Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

      ea0089c37
    • Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

      ea0089c38
    • Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients

      ea0089c39
    • TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors

      ea0089c40
    • SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis

      ea0089c41
    • Small Intestinal NET Recurrence - When Why and How?

      ea0089c42
    • Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

      ea0089c43
  • Population Science
  • • Cervical Neuroendocrine Carcinomas: A Population-Based Analysis of Clinicopathologic Characteristics and Survival Outcomes in Comparison with Conventional Cervical Malignancies

      ea0089p1
    • Factors Impacting Survival Outcomes of Islet Cell Carcinoma

      ea0089p2
    • Socioeconomic Factors, Treatment Modality, and Survival in Islet Cell Carcinoma: A National Cancer Database Analysis

      ea0089p3
    • Carcinoid Heart Disease in Patients Diagnosed with Small Bowel and Lung Neuroendocrine Tumors

      ea0089p4
    • Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late-Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States

      ea0089p5
    • Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

      ea0089p6
    • Feasibility of e-NET: A Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors

      ea0089p7
    • Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit

      ea0089p8
    • Lifestyle and Neuro-endocrine Tumor (NET) Development Within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort

      ea0089p9
    • Environmental Pollution and GEP-NENS - Is There an Association?

      ea0089p10
  • Other
  • • Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) - A Systematic Review and Meta-Analysis

      ea0089o1
    • The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors

      ea0089o2
    • Germline Pathogenic Variants in Patients with High-Grade (G3) Metastatic Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

      ea0089o3
    • Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response

      ea0089o4
    • Implementation of a Patient Advisor Program for Neuroendocrine Tumor Patients: Acceptability, Benefits and Potential Challenges

      ea0089o5
    • Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings

      ea0089o6
    • Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients

      ea0089o7
    • Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)

      ea0089o8
    • Leveraging Transcriptomics to Grade Pancreatic Neuroendocrine Neoplasms(NENs) and Assess Molecular Alterations Associated with Somatostatin Receptor(SSTR) Subtype Expression

      ea0089o9
    • Germline Cancer Testing in Unselected Patients with Neuroendocrine Neoplasms: A Multi-center Prospective Study

      ea0089o10
    • Pheo Para Alliance Patient Centered Research on Challenges for Those with Pheochromocytoma and Paraganglioma

      ea0089o11
    • An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?

      ea0089o12
  • Trials In Progress
  • • Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma

      ea0089t1
    • COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

      ea0089t2
    • Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

      ea0089t3
    • Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-[beta] and NIS (VSV-IFN[beta]-NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma

      ea0089t4
    • A Phase 2 Open-Label Study of Belzutifan (a HIF-2[alpha] Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors

      ea0089t5
    • ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

      ea0089t6
    • Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

      ea0089t7
    • Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

      ea0089t8
    • PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium - 177 DOTATATE Plus Chemotherapy vs PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

      ea0089t9
    • Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs)

      ea0089t10